v-DOS47

v-DOS47 is an experimental biologic anticancer drug candidate from Helix BioPharma that applies the company’s DOS47 immunoconjugate platform to generate a vascular-targeted agent designed to interfere with vascular endothelial growth factor receptor 2 (VEGFR2) signaling in tumors. It is described in pipeline databases as a VEGFR2 antagonist being explored at the discovery/preclinical stage for oncology indications, conceptually aiming to disrupt tumor angiogenesis and tumor-associated vasculature rather than acting directly on tumor cells. As of current public information, detailed structural composition, preclinical data, and specific tumor indications have not been extensively disclosed, and v-DOS47 has not yet entered clinical trials.